Thus, further investigation of stromal AR action in Gli1-lineage CAFs during ADT will help us better understand the molecular mechanisms underlying prostate cancer progression and hormone refractoriness, providing further insight into the development of potential and effective therapeutic strategies to co-target both tumor stromal and epithelial cells. The gene discussed is GLI1; the disease is prostate carcinoma.